piperacillin has been researched along with pefloxacin in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (46.15) | 18.7374 |
| 1990's | 3 (23.08) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Cattoir, V; Nordmann, P; Poirel, L | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Girlich, D; Nordmann, P; Poirel, L | 1 |
| Andremont, A; Boutan-Laroze, A; Culine, S; Droz, JP; Kattan, J; Ribrag, V | 1 |
| Andremont, A; Azab, M; Boutan-Laroze, A; Droz, JP; Kattan, J; Ribrag, V | 1 |
| Attisso, M; Bertrand, A; Beziau, H; Jonquet, O; Kassis, J; Perez, C; Pochet, I; Simeon De Buochberg, M | 1 |
| Amrani, R; Beklahia, C; Labia, R; Morand, A; Verchere-Beaur, C | 1 |
| Husson, M; Klastersky, J; Van der Auwera, P | 1 |
| Claeys, G; Van den Abeele, AM; Verschraegen, G | 1 |
| Duval, J; Leclercq, R; Soussy, CJ | 1 |
| Boisivon, A; Guiomar, C; Gutmann, L | 1 |
| Bayle, C; Bourhis, JH; Cartron, J; Gautier, E; Pico, JL; Tchernia, G | 1 |
1 trial(s) available for piperacillin and pefloxacin
| Article | Year |
|---|---|
Non-nephrotoxic empiric antimicrobial therapy in febrile neutropenic cancer patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Drug Therapy, Combination; Female; Fever; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Neoplasms; Neutropenia; Pefloxacin; Piperacillin; Vancomycin | 1992 |
12 other study(ies) available for piperacillin and pefloxacin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
Topics: Aged; Base Sequence; DNA Primers; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Female; Fluoroquinolones; France; Genes, Bacterial; Humans; Models, Genetic; Molecular Sequence Data; Plasmids | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
First isolation of the blaOXA-23 carbapenemase gene from an environmental Acinetobacter baumannii isolate.
Topics: Acinetobacter baumannii; beta-Lactamases; DNA, Bacterial; Escherichia coli; France; Genes, Bacterial; Water Microbiology | 2010 |
[Value of the combination of piperacillin and pefloxacin possibly followed by vancomycin in the treatment of febrile neutropenia in nephrotoxic chemotherapy].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bacterial Infections; Drug Therapy, Combination; Female; Fever; Humans; Male; Middle Aged; Neutropenia; Pefloxacin; Piperacillin; Prospective Studies; Renal Insufficiency; Vancomycin | 1992 |
[In vitro bactericidal effect of a piperacillin-pefloxacin combination against isolated strains of nosocomial pneumopathies in intensive care].
Topics: Cross Infection; Drug Synergism; Drug Therapy, Combination; Microbial Sensitivity Tests; Pefloxacin; Piperacillin | 1989 |
[Enzymologic aspect of piperacillin combinations].
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactamases; Drug Therapy, Combination; Enterobacter; Enzyme Induction; Hydrolysis; Norfloxacin; Pefloxacin; Piperacillin; Pseudomonas aeruginosa | 1986 |
Bactericidal activity and killing rate of serum in volunteers receiving pefloxacin alone or in combination with ceftazidime, piperacillin or mezlocillin against Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Blood Bactericidal Activity; Ceftazidime; Drug Interactions; Humans; Mezlocillin; Microbial Sensitivity Tests; Norfloxacin; Pefloxacin; Piperacillin; Pseudomonas aeruginosa; Time Factors | 1988 |
Comparative in vitro activity of the new quinolone fleroxacin (RO 23-6240).
Topics: Amikacin; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacteria; Cefaclor; Ceftazidime; Cefuroxime; Ciprofloxacin; Clavulanic Acids; Corynebacterium; Drug Combinations; Drug Resistance, Microbial; Fleroxacin; Norfloxacin; Pefloxacin; Piperacillin; Staphylococcus; Vancomycin | 1988 |
[In vitro antibacterial activity of piperacillin/quinolone combinations].
Topics: Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Drug Synergism; Escherichia coli; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; Oxazines; Pefloxacin; Piperacillin; Pseudomonas aeruginosa; Serratia marcescens | 1988 |
Interaction between piperacillin and pefloxacin or amikacin on the selection of resistant mutants of Pseudomonas aeruginosa.
Topics: Amikacin; beta-Lactamases; Drug Interactions; Microbial Sensitivity Tests; Mutation; Pefloxacin; Phenotype; Piperacillin; Pseudomonas aeruginosa; Selection, Genetic | 1988 |
Parvovirus B19 associated neutropenia. Treatment with Rh G-CSF.
Topics: Adenocarcinoma; Adult; Amikacin; Colonic Neoplasms; DNA, Viral; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Injections, Intravenous; Liver Neoplasms; Neutropenia; Parvoviridae Infections; Parvovirus B19, Human; Pefloxacin; Penicillanic Acid; Piperacillin; Recombinant Proteins; Tazobactam | 1997 |